Tag: pharmaceuticals

Consolidated Interim Report 1 January – 30 June 2025
Key points from the H1-2025 report (period 1 January - 30 June 2025)

Om Pharma Equity Group A/S

Ad hoc announcement pursuant to Art. 53 LR

Ad hoc-Mitteilung gemäss Art. 53 KR

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global AI in Synthetic Biology Market size & share revenue was valued at approximately USD 24.58 Billion in 2024 and is expected to reach USD 30.76 Billion in 2025 and is expected to reach around USD 192.95 Billion by 2034, at a CAGR of 28.63% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Ginkgo Bioworks, Amyris, Thermo Fisher Scientific, Illumina, GenScript, Synthetic Genomics, Novozymes, LanzaTech, Zymergen, Twist Bioscience, Codexis, Cambrian Biopharma, Moderna, Editas Medicine, Vertex Pharmaceuticals, CRISPR Therapeutics, Arbor Biotechnologies, Synthego, Evonik Industries, Cargill, Others and others.

Pratteln, Switzerland, 13 August, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Gen İlaç ve Sağlık Ürünleri San. ve Tic. A.Ş. (GEN) for the distribution and promotion of AGAMREE® (vamorolone) in Türkiye for the treatment of Duchenne muscular dystrophy (DMD) in patients four years of age and older.

VICTORIA, British Columbia, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced its financial results for the second quarter of 2025 and provided a business update. All dollar values are in U.S. dollars unless stated otherwise.